Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Other Accumulated Expenses (2016 - 2025)

IGC Pharma (IGC) has disclosed Other Accumulated Expenses for 12 consecutive years, with $146000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 81.61% to $146000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $146000.0, a 81.61% decrease, with the full-year FY2025 number at $1.0 million, up 382.21% from a year prior.
  • Other Accumulated Expenses was $146000.0 for Q3 2025 at IGC Pharma, down from $401000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.0 million in Q1 2025 to a low of $146000.0 in Q3 2025.
  • A 3-year average of $461555.6 and a median of $401000.0 in 2025 define the central range for Other Accumulated Expenses.
  • Biggest YoY gain for Other Accumulated Expenses was 382.21% in 2025; the steepest drop was 81.61% in 2025.
  • IGC Pharma's Other Accumulated Expenses stood at $210000.0 in 2023, then surged by 241.43% to $717000.0 in 2024, then crashed by 79.64% to $146000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Other Accumulated Expenses are $146000.0 (Q3 2025), $401000.0 (Q2 2025), and $1.0 million (Q1 2025).